New insulin tested for faster blood sugar control in chinese diabetes patients
NCT ID NCT04698018
First seen Dec 08, 2025 · Last updated May 16, 2026 · Updated 16 times
Summary
This study looked at how quickly a new fast-acting insulin (faster aspart) enters the blood compared to a standard insulin (NovoRapid) in 23 Chinese adults with type 1 or type 2 diabetes. Each participant received one injection of each insulin on separate visits, and blood samples were taken over 12 hours. The goal was to measure early insulin levels to see if the new insulin works faster.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Phase 1 Clinical Trial Centre
Shatin, New Territories, Hong Kong, Postal Code: NA, Hong Kong
-
Phase 1 Clinical Trial Centre
Shatin, New Territories, Hong Kong
-
Profil Institut für Stoffwechselforschung GmbH
Neuss, 41460, Germany
Conditions
Explore the condition pages connected to this study.